Lipocine Inc. Leases Disclosure
| (8) | Leases |
The Company has a non-cancelable operating lease for office space and laboratory facilities in Salt Lake City, Utah. On December 8, 2025, the term of the lease was extended through February 28, 2027.
Future minimum lease payments under the non-cancelable operating lease as of December 31, 2025 are:
| Operating | ||||
| Lease | ||||
| Year ending December 31: | ||||
| 2026 | $ | 385,139 | ||
| 2027 | 64,452 | |||
| Total minimum lease payments | $ | 449,591 | ||
The Company’s rent expense was $376,000 and $366,000 for the years ended December 31, 2025 and 2024, respectively.
Want the next Lipocine Inc. leases disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment Lipocine Inc.'s next filing hits EDGAR. No credit card, your email never gets sold.
About Leases Disclosures
Lease disclosures under ASC 842 provide a comprehensive view of a company's leased asset portfolio, including the split between operating and finance leases, discount rates used to present-value future payments, and the maturity schedule of lease obligations. This section reveals a significant source of off-balance-sheet commitments that were largely hidden before the current standard.
Key signals: the weighted-average discount rate affects the size of recorded lease liabilities — a higher rate reduces the reported obligation, so compare the chosen rate against the company's incremental borrowing rate. The operating versus finance lease mix affects both EBITDA and operating income presentation. Watch the maturity table for concentration risk: large payment cliffs in specific years may create cash flow pressure. Variable lease payments excluded from the liability measurement represent real obligations that do not appear on the balance sheet. Compare total lease costs against prior-year operating lease expense to assess the true economic burden.